Chronic Leukemia Perspective

 
 
  • Cancer Moonshot: We Have Liftoff Initial reaction to the Moonshot ranged from cynicism to guarded optimism, but no one denies that momentum is building for this national cancer initiative -- and Big Data are the rocket boosters.
  • Idelalisib Speed Bump: Shifting Gears in CLL   Dr Bruce Cheson discusses how the halt of six idelalisib trials because of adverse events, including deaths, affects research and patient management in CLL and follicular lymphoma.
  • Takeaways From ASH 2015: CAR T cell Therapy for Myeloma   Dr Saad Usmani highlights the key takeaways on CAR T cell therapy for myeloma from the 57th American Society of Hematology Annual Meeting.
  • Lymphoma Takeaways From ASH 2015: Immunotherapy   Dr Ann LaCasce gives a quick review of the most interesting immunotherapy studies in lymphoma at the 57th American Society of Hematology Annual Meeting.
  • In Lymphoma, Chemo Challenged by New Classes, New Combinations   Drs Cheson and Flinn discuss lymphoma clinical trial data presented at the ASH 2015 meeting.
  • Toward a Chemotherapy-Free Future for CLL   Drs Bruce Cheson and Kanti Rai discuss some of the highlights in chronic lymphocytic leukemia clinical research from the 2015 American Society of Hematology meeting.
  • ASH 2015: For Lymphoma, CLL, the Action Is in Combinations   Dr Bruce Cheson previews data to be presented at the upcoming ASH 2015 meeting, the most exciting of which are from studies using combination drugs.
  • CLL: It's the Best -- and Most Confusing -- of Times   Dr Bruce Cheson and Dr Susan O'Brien discuss data presented at the 2014 ASH meeting on chronic lymphocytic leukemia, with a focus on the CLL10 trial as well as ibrutinib, idelalisib, and ADT-199.
  • CLL's 'Very Unusual Year'   Dr. Bruce Cheson discusses how to choose among the new, exciting options available for the treatment of chronic lymphocytic leukemia: obinutuzumab, ibrutinib, and idelalisib.
  • Ibrutinib Stands Center Stage in CLL   Dr. John Gribben highlights new data on single and combination therapies for CLL as presented at EHA 2014.
  • Ibrutinib Results RESONATE in Refractory CLL   Drs. Bruce Cheson and Myron Czuczman discuss lymphoma and leukemia highlights from ASCO 2014, including the RESONATE and SEXIE trials and emerging antibody-drug conjugates.
  • ASCO® 2014: Aiming at Cancer’s Achilles Heel   Four leading oncologists discuss the top studies from ASCO 2014 and how immunotherapy is reshaping cancer care and practice.
  • What to Watch in Lymphoma, Leukemia   Dr. Bruce Cheson reviews a wealth of practice-changing and practice-confirming studies from the lymphoma and leukemia sessions at ASCO 2014.
  • FDA Sends Valentine to CLL Patients   The FDA approval of ibrutinib is a red-letter day for patients with relapsed chronic lymphocytic leukemia, because of the drug’s quick action and effectiveness, says Dr. Bruce Cheson.
  • Idelalisib Combo Rings Bells in Relapsed CLL   Patients with relapsed chronic lymphocytic leukemia, who were less able to undergo chemotherapy, had improved OS with a combination of idelalisib and rituximab, in a study reported by Dr Bruce Cheson.
  • Is Obinutuzumab the Drug to Watch in CLL? Drs. Cheson and Czuczman highlight data on obinutuzumab, ibrutinib, idelalisib, and emerging agents that are reshaping the leukemia and lymphoma landscape.
  • Novel Agents: Making the Benefit Last in CLL Drs. Susan O'Brien and Bruce Cheson discuss the exciting array of oral, well-tolerated, quick-acting therapies for CLL that provide durable if only partial remission.
  • Tailoring CLL Treatment to a TTT In CLL, combinations and sequences of agents are tailored to initial tumor load and response to therapy to optimize outcome, says Dr. Michael Hallek in a Medscape interview from ASH 2013.
  • CLL Combos: And the Winner Is… The question of which is better -- FRC or BR -- is settled, sort of, at ASH 2013, in a study discussed by Drs. Bruce Cheson and Clemens Wendtner.
  • ASH 2013: Big Year for CLL, Lymphoma   Highlighting major studies and a plethora of new drugs, Dr. Bruce Cheson predicts that ASH 2013 will be a big year for non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.